Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure

Orchestra BioMed Holdings, Inc.

Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.
Remaining up to $10M from future revenue earnouts based on milestone achievement.
Vivasure's PerQseal Elite received CE Mark and filed PMA with FDA; 0% major complications at 30 days.
Haemonetics closed acquisition on January 9, 2026; OBIO was strategic holder since formation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.